Patent: 10,106,620
✉ Email this page to a colleague
Summary for Patent: 10,106,620
| Title: | Blocking CD38 using anti-CD38 F(ab\')2 to protect NK cells |
| Abstract: | Provided herein are methods of inhibiting growth or proliferation of cells expressing CD38 by contacting the CD38-expressing cells with 1) NK cells bound to an anti-CD38 F(ab\').sub.2 fragment and 2) an anti-CD38 antibody, in either order or simultaneously. Also provided herein are methods of treating or inhibiting a hyperproliferative disorder or an autoimmune disorder in a subject by administering to the subject 1) NK cells bound to an anti-CD38 F(ab\').sub.2 fragment and 2) an anti-CD38 antibody, in either order or simultaneously. |
| Inventor(s): | Childs; Richard W. (Rockville, MD), Berg; Maria (Bethesda, MD), Espinoza Calderon; Luis (Bethesda, MD), Sasser; Kate (Spring House, PA), Attar; Ricardo (Spring House, PA) |
| Assignee: | The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC) Janssen Biotech, Inc. (Spring House, PA) |
| Application Number: | 15/319,344 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,106,620
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | DARZALEX | daratumumab | Injection | 761036 | November 16, 2015 | ⤷ Start Trial | 2035-06-15 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
